ArticleFrontiers in psychiatry2025
Neural markers of methylphenidate response in children with attention deficit hyperactivity disorder and the impact on executive function.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.Revista de neurologia · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. A core cognitive deficit in ADHD is executive function (EF) impairment, which significantly impacts daily life. Methylphenidate (MPH) is a widely used first-line treatment for ADHD, but objective biomarkers to assess treatment response are lacking. The aim of this study was to investigate the effects of MPH on executive function and identify potential neural biomarkers of response in children with ADHD using electroencephalogram (EEG). Methods: A total of 26 boys with ADHD (mean age 8.64 ± 1.30 years) participated in the study. All participants were treated with 18 mg/day of oral extended-release MPH in the morning for 8 weeks. Executive function was assessed using the BRIEF2 and Digit Span Test (DST), and event-related potentials (ERP) were measured at baseline and after 8 weeks of MPH treatment. Results: After 8 weeks of MPH treatment, significant improvements were observed in several executive function domains. BRIEF2 scores, including inhibition, self-monitoring, shifting, emotional control, initiation, working memory, planning/organization, task monitoring, and material organization, were significantly reduced ( Conclusions: The normalization of P300 latency following MPH treatment appears to be a reliable neural biomarker of positive treatment response in children with ADHD. MPH was associated with improvements in executive function, particularly in inhibitory control and working memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.